Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab

INTRODUCTION: At the clinical introduction of antiangiogenic agents as anticancer agents, no major toxicities were expected as merely just endothelial cells (ECs) in tumors would be affected. However, several (serious) toxicities became apparent, of which underlying mechanisms are largely unknown. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Walraven, Maudy, Homs, Marjolein Y. V., van der Veldt, Astrid A. M., Dekker, Henk, Koldenhof, Jose, Honeywell, Richard, Barendrecht, Arjan, Sebastian, Silvie A. E., Parr, Naomi, Koekman, Arnold C., Voest, Emile E., Roest, Mark, Korporaal, Suzanne J. A., Verheul, Henk M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878190/
https://www.ncbi.nlm.nih.gov/pubmed/29532289
http://dx.doi.org/10.1007/s10456-018-9598-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878190/
https://www.ncbi.nlm.nih.gov/pubmed/29532289
http://dx.doi.org/10.1007/s10456-018-9598-5

Ejemplares similares